Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
Private biotech company Prolynx appointed Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer to support the advancement of its ultra-long-acting obesity and metabolic disease portfolio. Harnest brings experience from Metagenomi (MGX), where he previously held senior finance roles, as well as from Cellectis and Totus Medicines.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.